Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MAGGIE: Apitolisib in recurrent or persistent endometrial carcinoma
NCT01455493Phase 2Completed
- Sponsor
- Genentech
- Start
- Dec 2011
- Primary completion
- Mar 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of apitolisib in endometrial carcinoma, sponsored by Genentech. Started Dec 2011; status: completed.
02
Drugs
apitolisib
03
Conditions
endometrial carcinoma
Beyond the preview
Go deeper on NCT01455493.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01455493.